title: Characterizing and understanding body weight patterns in patients treated with pregabalin.
abstract: OBJECTIVE
  We examined patterns of weight change among patients treated with pregabalin for up to 1 year.
  
  
  METHODS
  Patients with ≥1 pre-treatment weight measurement, ≥2 measurements in Period 1 (day 2-56), and ≥2 during Period 2 (day 57-356) were identified from pooled data of 106 studies including 43,525 patients. Seven patterns were developed and used for exploratory 'change point' analyses (day on-treatment when weight-change trend changed from initial trajectory) and to assess patterns of weight change by baseline weight/body mass index (BMI).
  
  
  RESULTS
  A total of 3187 patients (from 41 studies) were eligible. 98.9% of patients were described by three of the seven patterns. The majority of patients (2607/3187 [81.8%]) remained within ±7% of baseline weight ('Pattern 4'). Fewer patients (463/3187 [14.5%]) were 'delayed weight gainers' (exceeded 7% weight gain in Period 2 but not Period 1 ['Pattern 6']), fewer still (82/3187 [2.6%]) were 'early weight gainers' (exceeded ≥7% baseline weight in Period 1 and remained above 7% or continued to gain weight in Period 2 ['Pattern 7']). Overall weight gainers (Patterns 6, 7) experienced 1-year weight gain (median [% change]) of +6.20 kg [+9.12%] and 5.46 kg [+13.9%] vs. 2.22 kg [+2.10%] for non-weight gainers (Pattern 4). Average baseline weight/BMI was lower for weight gainers (Patterns 6, 7) versus other patterns. Early weight gainers (Pattern 7) had change point day at day 40 versus day 54 for Pattern 4 and day 69 for Pattern 6. Use of concomitant medications and influence of comorbid conditions on weight should be considered as inherent variables when interpreting the study.
  
  
  CONCLUSIONS
  The majority of patients treated with pregabalin (150-600 mg/day) for 1 year maintained weight within ±7% baseline weight. One in six patients gained ≥7% weight from baseline, and generally exceeded 7%, 2-12 months after treatment onset.
authors.affiliation: Rutgers University, Piscataway, NJ, USA.
authors.forename: Javier
authors.initials: J
authors.lastname: Cabrera
authors.forename: Birol
authors.initials: B
authors.lastname: Emir
authors.forename: Diana
authors.initials: D
authors.lastname: Dills
authors.forename: T Kevin
authors.initials: TK
authors.lastname: Murphy
authors.forename: Ed
authors.initials: E
authors.lastname: Whalen
authors.forename: Andrew
authors.initials: A
authors.lastname: Clair
mesh_terms: D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects*; D032882:Comprehension; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000453:epidemiology; D004828:Epilepsies, Partial / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000188:drug therapy / Q000453:epidemiology; D000069583:Pregabalin; D015430:Weight Gain / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid